New drug aims to slow kidney failure in chronic disease patients
NCT ID NCT07150338
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed trial tested a new drug called QRX-3 (Eseronate) in 45 people with chronic kidney disease stages 3-5. The goal was to see if the drug could slow the decline in kidney function and reduce protein in the urine. The study compared changes in kidney function over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QRX-3 (also called Eseronate)
- What this could lead to
- If it works, this could point toward a new treatment to slow kidney function loss in chronic kidney disease.
- What could go wrong
- This is a small, completed trial with only 45 participants. Results may not apply to all patients, and the drug may not be effective or safe in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (STAGE 3-4) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Premier Kidney clinic
Pasadena, Texas, 77504, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A softer path for kidney disease: could palliative care ease the burden?
- Can a 30-hour e-learning course equip family doctors to deliver better palliative care?
- Gut health supplement may calm inflammation in kidney dialysis patients
- Teen diabetes study seeks to uncover hidden triggers of kidney damage
- Thyroid hormones may hold clues to kidney disease progression
- New combo therapy may shield diabetic kidneys from damage